Literature DB >> 26237985

Priority Setting, Cost-Effectiveness, and the Affordable Care Act.

Govind Persad.   

Abstract

The Affordable Care Act (ACA) may be the most important health law statute in American history, yet much of the most prominent legal scholarship examining it has focused on the merits of the court challenges it has faced rather than delving into the details of its priority-setting provisions. In addition to providing an overview of the ACA's provisions concerning priority setting and their developing interpretations, this Article attempts to defend three substantive propositions. First, I argue that the ACA is neither uniformly hostile nor uniformly friendly to efforts to set priorities in ways that promote cost and quality. Second, I argue that the ACA does not take a single, unified approach to priority setting; rather, its guidance varies depending on the aspect of the healthcare system at issue (Patient Centered Outcomes Research Institute, Medicare, essential health benefits) and the factors being excluded from priority setting (age, disability, life expectancy). Third, I argue that cost-effectiveness can be achieved within the ACA's constraints, but that doing so will require adopting new approaches to cost-effectiveness and priority setting. By limiting the use of standard cost-effectiveness analysis, the ACA makes the need for workable rivals to cost-effectiveness analysis a pressing practical concern rather than a mere theoretical worry.

Entities:  

Mesh:

Year:  2015        PMID: 26237985     DOI: 10.1177/0098858815591511

Source DB:  PubMed          Journal:  Am J Law Med        ISSN: 0098-8588


  5 in total

1.  Community-based implementation of trauma-focused interventions for youth: Economic impact of the learning collaborative model.

Authors:  Alex R Dopp; Rochelle F Hanson; Benjamin E Saunders; Clara E Dismuke; Angela D Moreland
Journal:  Psychol Serv       Date:  2017-02

2.  Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape.

Authors:  Samilia Obeng-Gyasi; Sheetal M Kircher; Kelsey P Lipking; Benjamin J Keele; Al B Benson; Lynne I Wagner; Ruth C Carlos
Journal:  Cancer       Date:  2019-06-28       Impact factor: 6.860

Review 3.  Challenges of Cost-Effectiveness Analyses of Novel Therapeutics for Inherited Retinal Diseases.

Authors:  K Thiran Jayasundera; Rebhi O Abuzaitoun; Gabrielle D Lacy; Maria Fernanda Abalem; Gregory M Saltzman; Thomas A Ciulla; Mark W Johnson
Journal:  Am J Ophthalmol       Date:  2021-08-22       Impact factor: 5.258

4.  Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2019-10-31

5.  ICER, ISPOR AND QALYs: Tales of Imaginary Worlds.

Authors:  Paul C Langley
Journal:  Innov Pharm       Date:  2019-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.